33,871 Shares in Inspire Medical Systems, Inc. (NYSE:INSP) Bought by Trexquant Investment LP

Trexquant Investment LP bought a new position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 33,871 shares of the company's stock, valued at approximately $6,279,000. Trexquant Investment LP owned 0.11% of Inspire Medical Systems at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. First Horizon Advisors Inc. raised its stake in shares of Inspire Medical Systems by 885.7% during the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company's stock valued at $26,000 after acquiring an additional 124 shares during the last quarter. Harbour Investments Inc. raised its position in Inspire Medical Systems by 101.0% during the 4th quarter. Harbour Investments Inc. now owns 197 shares of the company's stock worth $37,000 after purchasing an additional 99 shares during the last quarter. AlphaQuest LLC lifted its holdings in Inspire Medical Systems by 7,275.0% during the 4th quarter. AlphaQuest LLC now owns 295 shares of the company's stock worth $55,000 after buying an additional 291 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of Inspire Medical Systems by 178.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 357 shares of the company's stock valued at $66,000 after buying an additional 229 shares during the period. Finally, Nisa Investment Advisors LLC raised its position in shares of Inspire Medical Systems by 37.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 368 shares of the company's stock worth $68,000 after acquiring an additional 100 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Transactions at Inspire Medical Systems

In other news, CTO John Rondoni sold 583 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the completion of the transaction, the chief technology officer now directly owns 10,424 shares in the company, valued at approximately $1,777,187.76. This represents a 5.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Randy Ban sold 25,584 shares of Inspire Medical Systems stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the transaction, the insider now owns 7,259 shares of the company's stock, valued at approximately $1,332,026.50. This represents a 77.90 % decrease in their position. The disclosure for this sale can be found here. 2.30% of the stock is currently owned by company insiders.

Inspire Medical Systems Trading Down 6.4 %

Shares of INSP stock traded down $9.87 during midday trading on Thursday, reaching $143.94. 176,111 shares of the stock were exchanged, compared to its average volume of 550,426. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $257.40. The firm has a market cap of $4.28 billion, a PE ratio of 83.01, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39. The company's 50 day moving average is $171.63 and its two-hundred day moving average is $186.14.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. As a group, equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on INSP. Truist Financial decreased their price target on Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating for the company in a report on Tuesday, February 11th. Robert W. Baird decreased their target price on Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating for the company in a research note on Tuesday, February 11th. Wells Fargo & Company cut their price target on Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 11th. KeyCorp reaffirmed an "overweight" rating and set a $234.00 price objective (down previously from $236.00) on shares of Inspire Medical Systems in a research report on Friday, January 24th. Finally, Morgan Stanley cut their target price on shares of Inspire Medical Systems from $230.00 to $220.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 11th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Inspire Medical Systems has a consensus rating of "Moderate Buy" and a consensus price target of $226.70.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.